1132-17-8

Basic information

• Product Name: 4-ETHOXY-BENZENESULFONYL CHLORIDE
• Synonyms: 4-ethoxybenzenesulfonyl chloride(SALTDATA: FREE);Benzenesulfonyl chloride, 4-ethoxy-;4-Ethoxybenzene-1-sulfonyl chloride
• CAS NO: 1132-17-8
• Molecular Formula: C₈H₉ClO₃S
• Molecular Weight: 220.68
• Mol File: 1132-17-8.mol

Chemical Properties

• Boiling Point: 327.9°C at 760 mmHg
• Flash Point: 152.1°C
• Appearance: /
• Density: 1.324g/cm³
• Vapor Pressure: 0.000375mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-ETHOXY-BENZENESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ETHOXY-BENZENESULFONYL CHLORIDE(1132-17-8)
• EPA Substance Registry System: 4-ETHOXY-BENZENESULFONYL CHLORIDE(1132-17-8)

Safety Data

• RIDADR: UN 3261 8 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1132-17-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-ETHOXY-BENZENESULFONYL CHLORIDE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its reactivity allows it to participate in a range of chemical reactions, facilitating the creation of diverse medicinal compounds.
Used in Organic Synthesis:
In the field of organic chemistry, 4-ETHOXY-BENZENESULFONYL CHLORIDE is used as a building block for synthesizing other organic compounds. Its unique structure contributes to the formation of complex organic molecules that are vital in various chemical applications.
Used in Chemical Research:
4-ETHOXY-BENZENESULFONYL CHLORIDE is utilized as a research compound in laboratories, where it aids scientists in understanding various chemical reactions and mechanisms, contributing to the advancement of chemical knowledge and innovation.

InChI:InChI=1/C8H9ClO3S/c1-2-12-7-3-5-8(6-4-7)13(9,10)11/h3-6H,2H2,1H3

Upstream product

• 46204-52-8 4-ethoxybenzene-1-sulfonic acid 
• 7790-94-5 chlorosulfonic acid 
• 103-73-1 Phenetole 
• 108-95-2 phenol 
• 825-90-1 sodium p-hydroxybenzenesulfonate 

Downstream Products

• 32176-33-3 1-(4-ethoxy-benzenesulfonyl)-piperidine 
• 105411-88-9 1-(4-Ethoxy-benzenesulfonyl)-5-fluoro-1H-pyrimidine-2,4-dione 
• 105411-92-5 5-Bromo-1-(4-ethoxy-benzenesulfonyl)-1H-pyrimidine-2,4-dione 
• 75531-60-1 4-Ethoxy-N-(4-hydroxy-3,5-diisopropyl-phenyl)-benzenesulfonamide 
• 699-09-2 4-ethoxy-benzenethiol 
• 22121-71-7 2-Nitrophenetol-4-sulfonylchlorid 
• 333310-92-2 N-(4-chloro-phenyl)-4-ethoxy-benzenesulfonamide 
• 415963-08-5 4-Ethoxy-N-[2-((2E)-2-{2-[hydroxy(oxido)amino]benzylidene}hydrazino)-2-oxoethyl]-N-(4-methylphenyl)benzenesulfonamide 

Relevant articles and documents

A practical synthesis of the dual matrix metalloprotease/tumor necrosis factor inhibitor MMP090

A practical 9-step synthesis of the dual matrix metalloprotease/ tumor necrosis factor inhibitor MMP090, trans-(R)-[[N-(4-ethoxyphenylsulfonyl)-N-(4- pyridinylmethyl)]amino]-N-hydroxy-4-propoxy cyclohexaneacetamide 10, was accomplished in 12% overall yield from D-4-hydroxyphenylglycine. Highlights include: (1) selective hydrogenation of D-hydroxyphenylglycine to afford predominantly the trans isomer without racemization; (2) virtually complete removal of the undesired cis diastereoisomer by fractional recrystallization of a TBS ether derivative of the functionalized cyclohexylglycine; (3) direct conversion of the TBS ether into the n-propyl ether in the presence of a catalytic amount of bismuth bromide in high yield; and (4) conversion of the carboxylic acid into the hydroxamic acid using an aqueous solution of hydroxylamine.

Design, synthesis, molecular docking and in vitro evaluation of n -(4-ethoxyphenylsulfonyl)pyrrolidine-2-carboxylic acid analogues as antiangiogenic and anticancer agents on multiple myeloma

In present work, N-(4-ethoxyphenylsulfonyl)pyrrolidine-2-carboxylic acid analogs were designed, synthesized and biologically evaluated as an antiangiogenic and anticancer agent on multiple myeloma. Compounds 3i, 3k and 3m exhibited the cytotoxic action on

N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT

Bis-aryl sulfonamide compounds and methods of using those compounds, e.g., in a method of enhancing or prolonging an immune response, are provided. For example, the compounds may be employed with a vaccine and optionally at least one other adjuvant and/or one or more TLR ligands, at least one MAP kinase inhibitor, or any combination thereof.

Identification and in Silico Binding Study of a Highly Potent DENV NS2B-NS3 Covalent Inhibitor

Dengue virus (DENV), an arthropod-borne flavivirus, has developed rapidly in the past few decades and becoming the most widespread arbovirus in the world. The vital role of NS2B-NS3 in virus replication and maturation of viral proteins makes it the most promising target for anti-DENV drug discovery. In the current work, a potent NS2B-NS3 covalent inhibitor 23 (IC50= 6.0 nM, kinac/Ki= 1581 M-1s-1) was discovered through the chemical modification of a published covalent inhibitor 1 (IC50= 500 nM, kinac/Ki= 156.1 M-1s-1), followed by in vitro assay. Further comprehensive structure-activity relationship analysis through covalent docking and molecular dynamics simulation provides informative understanding of the binding modes of covalent inhibitors targeting NS2B-NS3.

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof

The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.

Structure-Activity Relationship Studies to Identify Affinity Probes in Bis-aryl Sulfonamides That Prolong Immune Stimuli

Agents that safely induce, enhance, or sustain multiple innate immune signaling pathways could be developed as potent vaccine adjuvants or coadjuvants. Using high-throughput screens with cell-based nuclear factor κB (NF-κB) and interferon stimulating response element (ISRE) reporter assays, we identified a bis-aryl sulfonamide bearing compound 1 that demonstrated sustained NF-κB and ISRE activation after a primary stimulus with lipopolysaccharide or interferon-α, respectively. Here, we present systematic structure-activity relationship (SAR) studies on the two phenyl rings and amide nitrogen of the sulfonamide group of compound 1 focused toward identification of affinity probes. The murine vaccination studies showed that compounds 1 and 33 when used as coadjuvants with monophosphoryl lipid A (MPLA) showed significant enhancement in antigen ovalbumin-specific immunoglobulin responses compared to MPLA alone. SAR studies pointed to the sites on the scaffold that can tolerate the introduction of aryl azide, biotin, and fluorescent rhodamine substituents to obtain several affinity and photoaffinity probes which will be utilized in concert for future target identification and mechanism of action studies.

Synthesis and insecticidal activity in vitro and vivo of novel benzenesulfonyl derivatives based on potent target subunit H of V-ATPase

Two lead compounds with benzenesulfonamide were found through virtual screening based on the 3D structure of the subunit H of V-ATPase in previous study. 74 benzenesulfonyl derivatives were synthesized and their insecticidal activities were evaluated. The derivatives with propargyl substituents exhibit excellent insecticidal activities against Mythimna separata Walker. The LD50 values of compounds A5.7 (28.0 μg·g?1) and B5.7 (36.4 μg·g?1) were significantly less than that of Celangulin V (344.0 μg·g?1). Furthermore, Isothermal Titration Calorimetry (ITC) data indicate there is a strong binding affinity between A5.7 and V-ATPase Subunit H. These results demonstrate that it is a practical way to develop pesticides targeting at H subunit of V-ATPase.

Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic

Protein tyrosine phosphatase 1B (PTP1B) which plays an important role in the negative regulation of insulin and leptin pathway has emerged as a novel promising therapeutic target for the treatment of type 2 diabetes mellitus and obesity. Upon careful study, a series of novel scaffold and simple synthesis method inhibitors were discovered based on the analysis of X-ray crystal structures of PTP1B/inhibitor complexes and docking simulations. Among them, compound P7 exhibited high inhibitory activity (IC50 = 222 nM) with moderate selectivity (8-fold) over T-cell PTPase (TCPTP) through interacting with the A, B and C binding sites of PTP1B enzyme. Further studies on cellular activities revealed that compound P7 could enhance insulin-mediated IRβ phosphorylation and insulin-stimulated glucose uptake.

Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists

We report a novel chemical class of potent oxytocin receptor antagonists showing a high degree of selectivity against the closely related vasopressin receptors (Via, V1b, V2). An initial compound, 7, was shown to be active in an animal model of preterm labor when administered by the intravenous but not by the oral route. Stepwise SAR investigations around the different structural elements revealed one position, the arenesulfonyl moiety, to be amenable to structural changes. Consequently, this position was used to introduce a variety of substituents to improve the physicochemical properties. Some of the resulting analogues were found to be superior to 7 both in terms of potency in vitro and aqueous solubility, which translated into significantly improved efficacy in the animal model after intravenous and oral administration. The best compound, 73, potently inhibited oxytocin-induced uterine contractions in nonpregnant rats and reduced spontaneous uterine contractions in late-term pregnant rats.

Keratinocyte growth inhibitors and hydroxamic acid derivatives

This invention relates to a keratinocyte-proliferation inhibitor comprising as active ingredient a compound having an activity of inhibiting the solubilization of heparin-binding EGF-like growth factor bound to cell membranes and a compound of the formula (I); or pharmaceutically acceptable salt thereof, wherein R1, R2, R3 are hydrogen atom or alkyl and X is substituted benzene or the like.